These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28274530)

  • 1. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
    Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
    Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
    Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
    BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
    Otsubo K; Okamoto I; Hamada N; Nakanishi Y
    Respir Investig; 2018 Jul; 56(4):307-311. PubMed ID: 29764748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
    Ozawa Y; Akahori D; Koda K; Abe T; Hasegawa H; Matsui T; Tanahashi M; Niwa H; Yamada K; Yokomura K; Suda T
    Cancer Chemother Pharmacol; 2016 May; 77(5):1031-8. PubMed ID: 27048413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
    Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
    Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
    Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
    Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
    Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
    Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
    Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
    Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
    Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
    Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
    Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
    Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
    Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
    Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
    Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
    Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
    Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
    Fujimoto D; Shimizu R; Kato R; Sato Y; Kogo M; Ito J; Teraoka S; Otoshi T; Nagata K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Anticancer Res; 2015 Nov; 35(11):6261-6. PubMed ID: 26504060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Takahashi T
    Lung Cancer; 2018 Jul; 121():48-53. PubMed ID: 29858026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.